EMA Authorised: Refixia (nonacog beta pegol) — Novo Nordisk A/S

View source ↗

Summary

The European Medicines Agency authorised Refixia, a nonacog beta pegol product from Novo Nordisk A/S, for the treatment of Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refixia (Nonacog Beta Pegol (N9-GP))

Snippet

Status: Authorised. Therapeutic area: Hemophilia B. MAH: Novo Nordisk A/S. Decision date: 04/09/2025